Exelon
Product Images NDC 54868-5339

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Exelon (NDC 54868-5339). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Chemical Structure (Chemical Structure)

Chemical structure diagram of the active ingredient for the product Exelon, showing molecular components including benzene ring and side chains, along with a separate entity indicated as C4H6O6.*

FDA Label Image

Image Of Figure 1 (Figure 1)

A line graph depicting mean change from baseline in ADAS-cog scores over 26 weeks of treatment, comparing three groups: Exelon 6-12 mg, Exelon 1-4 mg, and placebo. The graph shows clinical improvement with higher doses and clinical decline with lower doses and placebo. The x-axis represents weeks during treatment and the y-axis shows mean change in ADAS-cog rating.*

FDA Label Image

Image Of Figure 2 (Figure 2)

A cumulative percentage of patients chart showing change from baseline in ADAS-cog scores over 30 days for Exelon treatment groups dosed at 1-4 mg/day and 6-12 mg/day compared to placebo. The chart includes a legend and an inset table summarizing mean changes in ADAS-cog scores for each group.*

FDA Label Image

Image Of Figure 3 (Figure 3)

A bar chart depicting the percentage of patients' responses to treatment grouped by CIBIC-Plus rating categories ranging from 'Markedly Improved' to 'Markedly Worse.' The chart compares results for Placebo, 1-4 mg, and 6-12 mg dose groups of Exelon.*

FDA Label Image

Image Of Figure 4 (Figure 4)

A line chart showing mean changes from baseline in ADCS-Cog Rating over 26 weeks of treatment with three groups: 6-12 mg, 1-4 mg, and placebo. The vertical axis ranges from clinical decline to clinical improvement, while the horizontal axis represents weeks during treatment. Error bars indicate standard error of the mean (SEM).*

FDA Label Image

Image Of Figure 5 (Figure 5)

A cumulative percentage graph showing the change from baseline in patients treated with Exelon at 1-4 mg/day and 6-12 mg/day doses compared to placebo. The x-axis represents change from baseline ranging from -25 to 30, and the y-axis shows cumulative percentage of patients up to 100%. The chart includes data points marked for placebo, 1-4 mg/day, and 6-12 mg/day treatment groups, with an inset table showing change values in ADAS-cog scores for each group at 7 and 4 points.*

FDA Label Image

Image Of Figure 6 (Figure 6)

A bar graph depicting the percentage of patients by CIBIC-Plus rating categories, comparing Placebo, 1-4 mg, and 6-12 mg groups. The x-axis lists improvement and worsening categories, while the y-axis shows the percentage of patients ranging from 0 to 40%.*

FDA Label Image

Image Of Figure 7 (Figure 7)

A line graph comparing the mean change from baseline in ADAS-cog total score over 24 weeks of treatment between Exelon and placebo groups. The x-axis represents weeks during treatment (0, 8, 16, 24), and the y-axis shows mean change with standard error margins. Exelon shows clinical improvement, while placebo trends toward clinical decline.*

FDA Label Image

Image Of Figure 8 (Figure 8)

A bar chart comparing the percentage of patients for Exelon versus placebo across ADCS-CGIC rating categories, including markedly improved, moderately improved, minimally improved, unchanged, minimally worse, moderately worse, and markedly worse.*

FDA Label Image

Image Of 1.5 mg Package Label (Package Label 01)

Exelon 1.5 mg capsule bottle label from Physicians Total Care, Inc. The label states it contains 30 capsules of rivastigmine tartrate, with a federal caution against dispensing without prescription. It includes storage instructions, a lot number, expiration date, barcode, and company contact details.*

FDA Label Image

Image Of 3 mg Package Label (Package Label 02)

Label for Exelon 3mg distributed by Physicians Total Care, Inc., Tulsa, OK. Includes lot number 000, expiration date 01/60, and a barcode with NDC 54868-5839-0. The label also references Novartis Consumer Health in Lincoln, NE.*

FDA Label Image

Image Of 4.5 mg Package Label (Package Label 03)

Exelon 4.5 mg capsules packaging label showing the Physicians Total Care logo and name. The label specifies the active ingredient as rivastigmine tartrate and indicates a package size of 30 capsules. There is a caution about federal law prohibiting dispensing without a prescription, along with dosage instructions and storage information text. A barcode and lot number with expiration date are visible. Labeler is Physicians Total Care, Inc.*

FDA Label Image

Image Of 6 mg Package Label (Package Label 04)

Label for Exelon 6mg medication distributed by Physicians Total Care, Inc. The label includes lot number 0000, expiration date 01/60, and indicates the manufacturer as Novartis Farmaceutica, S.A. in Barcelona, Spain. It features a barcode and associated numerical code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.